checkAd

     217  0 Kommentare Transactions in connection with share buy-back program

    Company Announcement

    COPENHAGEN, Denmark; March 11, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program.

    The share buy-back program is expected to be completed no later than March 15, 2024, and comprises up to 190,000 shares.

    The following transactions were executed under the program from February 26 to March 8, 2024:

      No. of shares Average price (DKK) Total value (DKK)
    Accumulated through last announcement 143,000   283,719,290
    March 4, 2024 9,000 1,968.78 17,719,020

    March 5, 2024 8,000 1,982.50 15,860,000

    March 6, 2024 6,000 1,979.27 11,875,620
    March 7, 2024 6,000 1,989.77 11,938,620
    March 8, 2024 5,000 2,020.67 10,103,350
    Total 34,000   67,496,610
    Accumulated under the program 177,000   351,215,900

    Details of each transaction are included as an appendix to this announcement.

    Following these transactions, Genmab holds 852,972 shares as treasury shares, corresponding to 1.29% of the total share capital and voting rights.

    The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 06 dated February 14, 2024.

    About Genmab
    Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies, and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines.

    Seite 1 von 3



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Transactions in connection with share buy-back program Company Announcement COPENHAGEN, Denmark; March 11, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share …

    Schreibe Deinen Kommentar

    Disclaimer